Debbie Rigby takes a look at the latest research relevant to pharmacy
A controlled study across 336 metropolitan pharmacies located in Perth aimed to devise and evaluate a team-based intervention to formalise the role of pharmacy assistants and to improve asthma guideline-based care in community pharmacy. The intervention did not improve practice related to device counselling or internal referral/pharmacist involvement.
BMJ Open 2016;6:e012369.
The results of this nationwide study from South Korea showed a trend that DPP-4 inhibitors might have a protective effect on bone metabolism compared with a sulfonylurea, when added to metformin (HR 0.82). Patients using a glitazone had a 60% increased risk of fracture compared with patients not using glitazones.
Osteoporosis International 2016;27(9):2709-15.
A Cochrane review meta-analysis of a modest number of trials in people with predominantly mild to moderate asthma suggests that vitamin D is likely to reduce both the risk of severe asthma exacerbation and healthcare use. Administration of vitamin D reduced the rate of exacerbations requiring systemic corticosteroids, and decreased the risk of having at least one exacerbation requiring an emergency department visit or hospitalisation or both. There was no effect of vitamin D on FEV1 or Asthma Control Test scores.
Cochrane Database of Systematic Reviews 2016, Issue 9.
Patients who have a fragility fracture are at high risk for subsequent fractures. This paper explored the use of prescription drugs associated with fracture risk before and after fragility fracture. More than half (55.7%) of patients were taking at least 1 drug that increases fall risk prior to the index fracture, while slightly less than half (42.2%) were taking at least 1 drug that decreases bone density. The authors concluded there is a missed opportunity to reduce the risk of a second fragility fracture through modification of exposure to prescription drugs.
JAMA Intern Med. Published online August 22, 2016.